LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

0.99 -4.81

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.98

Max

1.1

Põhinäitajad
By Trading Economics
Sissetulek	3.6M -34M
Müük	278K 1.9M
Kasumimarginaal	-1,786.576
Töötajad	181
EBITDA	979K -37M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+364.42% upside

Turustatistika
By TradingEconomics
Turukapital	18M 126M
Eelmine avamishind	5.8
Eelmine sulgemishind	0.99

Uudiste sentiment

By Acuity

50%

171 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2025, 21:34 UTC

Tulu

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13. nov 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13. nov 2025, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13. nov 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q EPS 52c >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q Sales $22.6B >JBS

13. nov 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13. nov 2025, 22:02 UTC

Tulu

Nu Holdings 3Q Net $783M >NU

13. nov 2025, 22:01 UTC

Tulu

Nu Holdings 3Q Rev $4.2B >NU

13. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13. nov 2025, 21:50 UTC

Tulu

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13. nov 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13. nov 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13. nov 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13. nov 2025, 21:33 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13. nov 2025, 21:31 UTC

Tulu

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q EPS 34c >FIGR

13. nov 2025, 21:23 UTC

Tulu

Intchains Group 3Q Rev $1.3M >ICG

13. nov 2025, 21:03 UTC

Tulu

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13. nov 2025, 21:02 UTC

Tulu

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Rev $6.8B >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Gross Margin 48.0% >AMAT

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

364.42% tõus

12 kuu keskmine prognoos

Keskmine 4.83 USD 364.42%

Kõrge 7 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

171 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.